Literature DB >> 26893870

Identification of DLC-1 expression and methylation status in patients with non-small-cell lung cancer.

Hongxiang Feng1, Zhenrong Zhang1, Xiaowei Wang1, Deruo Liu1.   

Abstract

In order to determine whether the deleted in liver cancer-1 (DLC-1) gene is deregulated in non-small-cell lung carcinoma (NSCLC) and to assess the contribution of molecular alterations in DLC-1 to lung carcinogenesis, a total of 84 tissue specimens (30 NSCLC and 30 corresponding adjacent normal tissues; 5 benign tumor and 5 corresponding adjacent normal tissues; and 10 pulmonary bullae and 4 corresponding adjacent normal tissues), were obtained from 45 patients who underwent curative surgical resection. DLC-1 mRNA expression was evaluated by reverse transcription-quantitative polymerase chain reaction (PCR) and its protein level was assessed by western blot analysis. A significant downregulation of DCL-1 at the mRNA and protein levels was observed in NSCLC tissues when compared to benign lung tumors and normal lung tissues (P<0.001). To further determine whether the decreased expression of DLC-1 at the mRNA and protein levels is associated with the methylation of its promoter, methylation-specific PCR was performed following extraction of genomic DNA from the samples. DLC-1 promoter methylation was identified in 7 of the 30 (23.3%) NSCLC tissue samples, but not in the corresponding adjacent normal tissues from NSCLC patients or in lung tissues from non-NSCLC patients. Our data indicated that DLC-1 hypermethylation may play a crucial role in lung carcinogenesis and may be a target for the treatment of NSCLC.

Entities:  

Keywords:  deleted in liver cancer-1; expression; methylation; non-small-cell lung carcinomas

Year:  2015        PMID: 26893870      PMCID: PMC4733962          DOI: 10.3892/mco.2015.681

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase.

Authors:  P M Vertino; R W Yen; J Gao; S B Baylin
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

3.  CpG island methylation and expression of tumour-associated genes in lung carcinoma.

Authors:  Reinhard Dammann; Maria Strunnikova; Undraga Schagdarsurengin; Matthias Rastetter; Mirko Papritz; Uwe E Hattenhorst; Hans-Stefan Hofmann; Rolf-Edgar Silber; Stefan Burdach; Gesine Hansen
Journal:  Eur J Cancer       Date:  2005-05       Impact factor: 9.162

4.  The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.

Authors:  T J Seng; J S W Low; H Li; Y Cui; H K Goh; M L Y Wong; G Srivastava; D Sidransky; J Califano; R D M Steenbergen; S Y Rha; J Tan; W-S Hsieh; R F Ambinder; X Lin; A T C Chan; Q Tao
Journal:  Oncogene       Date:  2006-07-24       Impact factor: 9.867

5.  Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.

Authors:  Shinji Kikuchi; Daisuke Yamada; Takeshi Fukami; Tomoko Maruyama; Akihiko Ito; Hisao Asamura; Yoshihiro Matsuno; Masataka Onizuka; Yoshinori Murakami
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

6.  DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas.

Authors:  Bao-Zhu Yuan; Amy M Jefferson; Kimberly T Baldwin; Snorri S Thorgeirsson; Nicholas C Popescu; Steven H Reynolds
Journal:  Oncogene       Date:  2004-02-19       Impact factor: 9.867

7.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer.

Authors:  Mónica Castro; Laura Grau; Patricia Puerta; Liliana Gimenez; Julio Venditti; Silvia Quadrelli; Marta Sánchez-Carbayo
Journal:  J Transl Med       Date:  2010-09-17       Impact factor: 5.531

8.  Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.

Authors:  Sonata Jarmalaite; Annamaria Kannio; Sisko Anttila; Juozas R Lazutka; Kirsti Husgafvel-Pursiainen
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

9.  Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions.

Authors:  Patricia García; Carlos Manterola; Juan Carlos Araya; Miguel Villaseca; Pablo Guzmán; Antonio Sanhueza; Melanie Thomas; Héctor Alvarez; Juan Carlos Roa
Journal:  Mol Carcinog       Date:  2009-01       Impact factor: 4.784

10.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

View more
  4 in total

1.  Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma.

Authors:  Chundi Gao; Jing Zhuang; Huayao Li; Cun Liu; Chao Zhou; Lijuan Liu; Changgang Sun
Journal:  Cancer Cell Int       Date:  2018-11-26       Impact factor: 5.722

2.  A functional methylation signature to predict the prognosis of Chinese lung adenocarcinoma based on TCGA.

Authors:  Ke Wang; Ying Liu; Guanzhong Lu; Jinrong Xiao; Jiao Huang; Lin Lei; Ji Peng; Yangkai Li; Sheng Wei
Journal:  Cancer Med       Date:  2021-12-02       Impact factor: 4.452

3.  Downregulation of microRNA-301a inhibited proliferation, migration and invasion of non-small cell lung cancer by directly targeting DLC1.

Authors:  Zhuyu Wu; Yaojun Li; Guojun Zhang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

4.  High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC.

Authors:  Li Sun; Jing Sun; Jun-Ding Song
Journal:  Mol Med Rep       Date:  2019-04-10       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.